Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen.
Olayinka OkelejiAmber GibsonCesar NunezMiriam B GarciaMichael E RothBranko CuglievanDavid C McCallPublished in: Pediatric blood & cancer (2024)
Keyphrases